Premium Essay

FDA 101 Medication Errors Summary

Submitted By
Words 482
Pages 2
In the article FDA 101: Medication Errors, a medication is any error that is preventable that may cause or lead to incorrect medication use or harm. MedWatch is the error reporting program where any physician, pharmacist, pharmacy technician, other medical personnel and the general public can voluntarily submit a medication adverse event or error. Since the year 2000, 95,000 reports of medication errors have been reported to MedWatch.1 The FDA has partnered with the U.S. Pharmacopeia and the Institute for Safe Medication Practices to track medication errors, the USP/ISMP has its own Voluntary Medication Error Reporting Program (MERP).1 All errors received through MERP are sent directly to MedWatch. Through these programs they monitor errors and evaluate them, to educate the public about approaches to prevent these errors in the future. …show more content…
Nurses use the 5 rights: The Right time, the Right patient, the Right drug, the Right route, the Right strength, to help prevent errors. Orders should be read three times before selecting a drug, to avoid an error. The FDA says that most medication errors occur because of multiple and complex factors.1
In 2008, the misuse of the prescription drug Tussionex Pennkinetic Extended-Release Suspension. This cough syrup caused adverse events and deaths of children and adults. This was due to an overdose of hydrocodone, a narcotic drug that can cause severe breathing problems. When a prescriber ordered too much hydrocodone for a cough to be taken at once or more frequently than recommended the results were adverse. The cough medicine was also prescribed to children under the age of 6, even though it was listed as not for use in children under the age of

Similar Documents

Premium Essay

To Err Is Human

...http://www.nap.edu/catalog/9728.html We ship printed books within 1 business day; personal PDFs are available immediately. To Err Is Human: Building a Safer Health System Linda T. Kohn, Janet M. Corrigan, and Molla S. Donaldson, Editors; Committee on Quality of Health Care in America, Institute of Medicine ISBN: 0-309-51563-7, 312 pages, 6 x 9, (2000) This PDF is available from the National Academies Press at: http://www.nap.edu/catalog/9728.html Visit the National Academies Press online, the authoritative source for all books from the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, and the National Research Council: • Download hundreds of free books in PDF • Read thousands of books online for free • Explore our innovative research tools – try the “Research Dashboard” now! • Sign up to be notified when new books are published • Purchase printed books and selected PDF files Thank you for downloading this PDF. If you have comments, questions or just want more information about the books published by the National Academies Press, you may contact our customer service department tollfree at 888-624-8373, visit us online, or send an email to feedback@nap.edu. This book plus thousands more are available at http://www.nap.edu. Copyright © National Academy of Sciences. All rights reserved. Unless otherwise indicated, all materials in this PDF File are copyrighted by the National Academy of Sciences. Distribution, posting, or copying...

Words: 104719 - Pages: 419

Premium Essay

How Fda Evaluates Drug Approvals

...Asthma diagnosis and treatment Current perspectives Asthma diagnosis and treatment 34 ‘‘Black box’’ 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk Shirley Murphy, MD, and Rosemary Roberts, MD Silver Spring, Md A prominently displayed boxed warning, the so-called ‘‘black box,’’ is added to the labeling of drugs or drug products by the Food and Drug Administration when serious adverse reactions or special problems occur, particularly those that may lead to death or serious injury. Healthcare providers are often not knowledgeable about the origin, meaning, and implications of these ‘‘black box’’ warnings. In this review, our goal is to provide insight into how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. We discuss drug labeling, the emphasis on safety throughout the drug approval process, legislative initiatives for safe use of drugs in children, and postmarketing safety surveillance. In addition, we encourage health care providers to report drug reactions to the Food and Drug Administration’s MedWatch program. A discussion of new Food and Drug Administration initiatives to improve drug safety processes and methods to serve the public better are highlighted. (J Allergy Clin Immunol 2006;117:34-9.) Key words: Food and Drug Administration, adverse drug reactions, MedWatch, ‘‘black box’’ warning, drug labeling, drug benefit/risk, risk management, postmarketing surveillance, drug development ...

Words: 5617 - Pages: 23

Premium Essay

Week 5 Mle Assignment

...key terms and: 1. 2. 3. 4. 5. 6. 7. 8. 9. List the five steps of the office visit workflow in a physician office. Discuss the advantages of pre-visit scheduling and information collection for patients and office staff. Describe the process of electronic check-in. Explain how electronic health records make documenting patient exams more efficient. Explain what occurs during patient checkout. Explain what two events take place during the post-visit step of the visit workflow. Describe the advantages of computer-assisted coding. List three decision-support tools the EHRs contain to provide patients with safe and effective health care. List four important safety checks that an EHR’s e-prescribing feature can perform when a physician selects a new medication for a patient. KEY TERMS chronic diseases disease management (DM) clinical guidelines formulary computer-assisted coding point-of-care...

Words: 12974 - Pages: 52

Premium Essay

Medical

...2. 3. 4. 5. 6. 7. 8. 9. List the five steps of the office visit workflow in a physician office. Discuss the advantages of pre-visit scheduling and information collection for patients and office staff. Describe the process of electronic check-in. Explain how electronic health records make documenting patient exams more efficient. Explain what occurs during patient checkout. Explain what two events take place during the post-visit step of the visit workflow. Describe the advantages of computer-assisted coding. List three decision-support tools the EHRs contain to provide patients with safe and effective health care. List four important safety checks that an EHR’s e-prescribing feature can perform when a physician selects a new medication for a patient. KEY TERMS chronic diseases disease management (DM) clinical...

Words: 12974 - Pages: 52

Free Essay

Strategic Entry Deterrence and the Behavior of

...American Economic Journal: Microeconomics 3 (February 2011): 1–36 http://www.aeaweb.org/articles.php?doi=10.1257/mic.3.1.1 Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration† By Glenn Ellison and Sara Fisher Ellison* This paper develops a new approach to testing for strategic entry deterrence and applies it to the behavior of pharmaceutical incumbents before patent expiration. It examines a cross section of markets, determining whether behavior is nonmonotonic in market size. Under some conditions, investment levels will be monotone in market size if firms do not invest to deter entry. Strategic investments to deter entry, however, may result in nonmonotonic investment because they are unnecessary in small markets, and impossible in large ones. Consistent with an entry-deterrence motivation is the finding that incumbents in medium-sized markets advertise less prior to patent expiration. (JEL D92, G31, L11, L21, L65) T he insight that firms may make “strategic investments” to alter future competitive conditions is one of the most fundamental ideas in industrial organization. Jean Tirole’s (1988) chapter reviewing arguments about how excess capacity, capital structure, advertising, contractual practices, learning-by-doing, and other actions can be used to deter entry is easily the longest in the text.1 Strategic investment models are difficult to test directly, however, and the vast majority of this literature is theoretical...

Words: 15200 - Pages: 61

Premium Essay

Accounting

...SACHS.DOCX (DO NOT DELETE) 8/1/2011 2:07 PM RESCUING THE STRONG PRECAUTIONARY PRINCIPLE FROM ITS CRITICS Noah M. Sachs* The Strong Precautionary Principle, an approach to risk regulation that shifts the burden of proof on safety, can provide a valuable framework for preventing harm to human health and the environment. Cass Sunstein and other scholars, however, have consistently criticized the Principle, rejecting it as paralyzing, inflexible, and extreme. In this reassessment of the Strong Precautionary Principle, I highlight the significant benefits of the Principle for risk decision making, with the aim of rescuing the Principle from its dismissive critics. The Principle sends a clear message that firms must research the health and environmental risks of their products, before harm occurs. It does not call for the elimination of all risk, nor does it ignore tradeoffs, as Sunstein has alleged. Rather, through burden shifting, the Principle legitimately requires risk creators to research and justify the risks they impose on society. By exploring where the Principle already operates successfully in U.S. law—examples often overlooked by the critics—I highlight the Principle’s flexibility and utility in regulatory law. This Article uses chemical regulation as a case study in how the Principle can guide Congress in an ongoing controversy. Congress is considering a major overhaul of the flawed Toxic Substances Control Act of 1976 (TSCA), and this change could be one of the most significant...

Words: 29197 - Pages: 117

Premium Essay

Evidence-Park & Waltz

...RULE 101. SCOPE; DEFINITIONS (a) Scope. These rules apply to proceedings in United States courts. The specific courts and proceedings to which the rules apply, along with exceptions, are set out in Rule 1101. (b) Definitions. In these rules: (1) “civil case” means a civil action or proceeding; (2) “criminal case” includes a criminal proceeding; (3) “public office” includes a public agency; (4) “record” includes a memorandum, report, or data compilation; (5) a “rule prescribed by the Supreme Court” means a rule adopted by the Supreme Court under statutory authority; and (6) a reference to any kind of written material or any other medium includes electronically stored information. RULE 102. PURPOSE These rules should be construed so as to administer every proceeding fairly, eliminate unjustifiable expense and delay, and promote the development of evidence law, to the end of ascertaining the truth and securing a just determination. RULE 103. RULINGS ON EVIDENCE (a) Preserving a Claim of Error. A party may claim error in a ruling to admit or exclude evidence only if the error affects a substantial right of the party and: (1) if the ruling admits evidence, a party, on the record: (A) timely objects or moves to strike; and (B) states the specific ground, unless it was apparent from the context; or (2) if the ruling excludes evidence, a party informs the court of its substance by an offer of proof, unless the substance was apparent from the context. (b) Not Needing...

Words: 49736 - Pages: 199

Premium Essay

Nanoparticles in Drug Targeting

...CONTENTS Title Page.no 1. Introduction To Nanoparticles (2) 2. Nanoparticulate systems For Targeting (13) 3. Drug Targeting (25) 4. Approaches To Drug Targeting (29) 5. Nanoparticle Drug Delivery Market (47) 6. Future Barriers And Challenges (48) 7. Various Nanopharmaceuticals And Their Case Studies (49) 8. NanoDrug Patenting (54) 9. Conclusion (57) 10. Bibliography (58) NANOPARTICLES IN DRUG TARGETING 1. INTRODUCTION NANOPARTICLES * Nanoparticles are in solid state and are either in amorphous or crystalline They include Nanocapsules and Nanospheres.They are able to adsorb or encapsulate a drug thus protecting it against chemical and enzymatic degradation...

Words: 10751 - Pages: 44

Free Essay

Operations

...Locker−Kienzler: Business and Administrative Communication, Eighth Edition III. Basic Business Messages 10. Informative and Positive Messages © The McGraw−Hill Companies, 2008 C H A P T E R 10 Informative and Positive Messages Learning Objectives After studying this chapter, you will know: 1 When to use common business media. 2 How to use the chosen channel effectively. 3 How to write letters and memos. 4 How to compose some of the common varieties of informative and positive messages. Locker−Kienzler: Business and Administrative Communication, Eighth Edition III. Basic Business Messages 10. Informative and Positive Messages © The McGraw−Hill Companies, 2008 IN THE NEWS All in a Day’s (Communication) Work im Donald, CEO and president of Starbucks, He is also known for visiting his stores, where he knows the value of informative and positive dons the green apron, goes behind the counter, and talks messages. His days are full of them. On the with employees. When he is in Seattle, he visits about day of his Fortune magazine interview, around 20 Starbucks a week; when he is traveling, about 10 a day. 6 AM he left a voice mail for Although you probably don’t 100 regional managers, wrote want his e-mail load, you might personal thank-you notes to “He gets 200–250 emails daily and appreciate his meeting time lim25 employees, and signed 500 responds personally to 75% of them.” its. He books meetings for an birthday cards. He will sign hour...

Words: 20520 - Pages: 83

Free Essay

Mckesson Annual Report

...Annual Report Fiscal Year Ended March 31, 2011 “Our results in fiscal 2011 extend our track record of growing EPS, which we have increased at a 13.9% compound annual growth rate since fiscal 2007.” John H. Hammergren, Chairman, President and Chief Executive Officer, McKesson Corporation Financial Results Five-Year Total Revenue (in millions) Five-Year EPS* *Diluted earnings per share from continuing operations, as displayed above, excludes adjustments for litigation charges (credits) net (“EPS”). For supplemental financial data and corresponding reconciliation to U.S. generally accepted accounting principles (“GAAP”), see Appendix A to this 2011 Annual Report. Non-GAAP measures should be viewed in addition to, and not as an alternative for, financial results prepared in accordance with GAAP. Total Stockholder Return** **The percentages displayed represent total annualized stockholder return for each period presented, including the reinvestment of dividends. Dear Fellow Stockholders, I am pleased to report that McKesson delivered another strong performance in fiscal 2011, marked by outstanding execution in Distribution Solutions, continued success in expanding our relationships with customers and suppliers, and near record levels of capital deployment, including the $2.1 billion acquisition of US Oncology, our largest acquisition in a decade. McKesson generated revenues of $112.1 billion and exceeded expectations for both earnings and cash flow. Earnings...

Words: 66785 - Pages: 268

Free Essay

Cvs 10k Form

...UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2014 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-01011 CVS HEALTH CORPORATION (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) One CVS Drive, Woonsocket, Rhode Island (Address of principal executive offices) 05-0494040 (I.R.S. Employer Identification No.) 02895 (Zip Code) (401) 765-1500 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: Common Stock, par value $0.01 per share Title of each class New York Stock Exchange Name of each exchange on which registered Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for...

Words: 59685 - Pages: 239

Premium Essay

Singapore Healthcare Report

...this publication is copyrighted in the name of Business Monitor International, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. DISCLAIMER All information contained in this publication has been researched and compiled from sources believed to be accurate and reliable at the time of publishing. However, in view of the natural scope for human and/or mechanical error, either at source or during production, Business Monitor International accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions affecting any part of the publication. All information is provided without warranty, and Business Monitor International makes no representation of warranty of any kind as to the accuracy or completeness of any information hereto contained. Singapore Pharmaceuticals & Healthcare Report Q3 2010 ©...

Words: 29653 - Pages: 119

Premium Essay

Who Drug Evaluation

...WHO DRUG INFORMATION V O L U M E 10 N U M B E R 4 19 9 6 P R O P O S E D INN LIST 76 INTERNATIONAL NONPROPRIETARY NAMES FOR P H A R M A C E U T I C A L S U B S T A N C E S WORLD HEALTH ORGANIZATION • GENEVA Volume 10, Number 4, 1996 World Health Organization, Geneva WHO Drug Information Contents General Policy Topics Meeting the challenge of biotechnology 175 Regulatory Matters Acellular pertussis vaccine for infants Breath test for Helicobacter pylori Restrictions on use of anorectics Coumarin: regulatory action Laxatives: reclassification of common ingredients Is melatonin a prescription drug? NSAIDS, antimicrobials and angioedema Drug-induced liver disease Fluoxetine and hepatitis Hepatitis B vaccine and musculoskeletal reactions Pyrithyldione-diphenhydramine and agranulocytosis Roxithromycin associated with cardiac arrhythmias 187 187 187 188 189 189 189 189 190 190 190 190 Reports on Individual Drugs Confirmation of increased chloroquine resistance in South Africa Which malaria drug for children? Post-malaria neurological syndrome and mefloquine Driving ability in cancer patients treated with morphine Hormone replacement therapy and venous thromboembolism 177 177 177 178 179 Safety Issues Documentation requirements for approval: safety Drug safety monitoring centres 180 181 Recent Publications WHO Expert Committee on Specifications for Pharmaceutical Preparations: Thirty-fourth report International Nonproprietary...

Words: 17347 - Pages: 70

Premium Essay

The Oswestry Disability Index

...outcome measurement ● To consider what is actually measured by this and similar instruments ● Study Design. The Oswestry Disability Index (ODI) has become one of the principal condition-specific outcome measures used in the management of spinal disorders. This review is based on publications using the ODI identified from the authors’ personal databases, the Science Citation Index, and hand searches of Spine and current textbooks of spinal disorders. Objectives. To review the versions of this instrument, document methods by which it has been validated, collate data from scores found in normal and back pain populations, provide curves for power calculations in studies using the ODI, and maintain the ODI as a gold standard outcome measure. Summary of Background Data. It has now been 20 years since its original publication. More than 200 citations exist in the Science Citation Index. The authors have a large correspondence file relating to the ODI, that is cited in most of the large textbooks related to spinal disorders. Methods. All the published versions of the questionnaire were identified. A systematic review of this literature was made. The various reports of validation were collated and...

Words: 12598 - Pages: 51

Premium Essay

Gmos: Truth vs. Myth

...GMO MYTHS AND TRUTHS An evidence-based examination of the claims made for the safety and efficacy of genetically modified crops Michael Antoniou Claire Robinson John Fagan June 2012 GMO Myths and Truths An evidence-based examination of the claims made for the safety and efficacy of genetically modified crops Version 1.3 by Michael Antoniou Claire Robinson John Fagan © Earth Open Source www.earthopensource.org 2nd Floor 145–157, St John Street, London EC1V 4PY, United Kingdom Contact email: claire.robinson@earthopensource.org June 2012 Disclaimer The views and opinions expressed in this paper, or otherwise published by EOS, are those of the authors and do not represent the official policy, position, or views of other organizations, universities, companies, or corporations that the authors may be affiliated with. GMO Myths and Truths 2 About the authors Michael Antoniou, PhD is reader in molecular genetics and head, Gene Expression and Therapy Group, King’s Cols: lege London School of Medicine, London, UK. He has 28 years’ experience in the use of genetic engineering technology investigating gene organisation and control, with over 40 peer reviewed publications of original work, and holds inventor status on a number of gene expression biotechnology patents. Dr Antoniou has a large network of collaborators in industry and academia who are making use of his discoveries in gene control mechanisms for the production of research, diagnostic and therapeutic products...

Words: 78055 - Pages: 313